Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CNTB NASDAQ:HURA NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.440.0%$20.71$8.61▼$23.47$151.47M0.52292,544 shs517,172 shsCNTBConnect Biopharma$2.17-5.7%$2.59$0.75▼$3.82$136.63M-0.22194,956 shs277,505 shsHURATuHURA Biosciences$1.97-10.0%$2.28$0.41▼$3.90$125.14M0.01469,986 shs1.07 million shsZYBTZhengye Biotechnology$0.83+0.1%$0.92$0.68▼$13.08$39.36M-2.429,480 shs7,510 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-0.04%0.00%+5.59%+100.00%+134.42%CNTBConnect Biopharma-5.65%-12.85%-12.50%-12.50%+181.31%HURATuHURA Biosciences-10.05%-12.83%-22.44%+31.33%-30.14%ZYBTZhengye Biotechnology+3.17%+0.18%-15.69%+10.73%-87.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.440.0%$20.71$8.61▼$23.47$151.47M0.52292,544 shs517,172 shsCNTBConnect Biopharma$2.17-5.7%$2.59$0.75▼$3.82$136.63M-0.22194,956 shs277,505 shsHURATuHURA Biosciences$1.97-10.0%$2.28$0.41▼$3.90$125.14M0.01469,986 shs1.07 million shsZYBTZhengye Biotechnology$0.83+0.1%$0.92$0.68▼$13.08$39.36M-2.429,480 shs7,510 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-0.04%0.00%+5.59%+100.00%+134.42%CNTBConnect Biopharma-5.65%-12.85%-12.50%-12.50%+181.31%HURATuHURA Biosciences-10.05%-12.83%-22.44%+31.33%-30.14%ZYBTZhengye Biotechnology+3.17%+0.18%-15.69%+10.73%-87.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 1.80Reduce$22.65-3.37% DownsideCNTBConnect Biopharma 2.86Moderate Buy$7.20231.80% UpsideHURATuHURA Biosciences 2.67Moderate Buy$9.00356.85% UpsideZYBTZhengye Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ZYBT, ASRT, CNTB, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/15/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.805/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/1/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$118.71M1.28$0.02 per share1,433.64$14.63 per share1.60CNTBConnect Biopharma$60K2,277.05N/AN/A$0.75 per share2.89HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AZYBTZhengye Biotechnology$16.64M2.37N/AN/A$0.93 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$30.38M-$5.69N/A21.12N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)CNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)HURATuHURA Biosciences-$30.05M-$0.61N/AN/AN/AN/A-156.12%-105.38%8/13/2026 (Estimated)ZYBTZhengye Biotechnology-$9.98MN/AN/AN/AN/AN/AN/AN/AN/ALatest ZYBT, ASRT, CNTB, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026HURATuHURA Biosciences-$0.12-$0.13-$0.01-$0.13N/AN/A5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million4/28/2026Q4 2025ZYBTZhengye BiotechnologyN/A-$0.0750N/A-$0.0750N/A$3.97 million3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/31/2026Q4 2025HURATuHURA Biosciences-$0.1233-$0.13-$0.0067-$0.10N/AN/A3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.521.821.57CNTBConnect Biopharma0.013.233.23HURATuHURA BiosciencesN/A1.151.15ZYBTZhengye Biotechnology0.031.140.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CNTBConnect Biopharma58.72%HURATuHURA Biosciences0.62%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipASRTAssertio5.70%CNTBConnect Biopharma22.60%HURATuHURA Biosciences0.20%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio206.46 million6.09 millionOptionableCNTBConnect Biopharma11062.96 million48.73 millionOptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/AZYBTZhengye Biotechnology27847.39 millionN/AN/AZYBT, ASRT, CNTB, and HURA HeadlinesRecent News About These CompaniesZhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 NoticeJune 4 at 4:30 PM | tipranks.comZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJune 4 at 4:05 PM | globenewswire.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsApril 28, 2026 | prnewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026April 6, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureApril 6, 2026 | globenewswire.comZhengye Biotechnology Holding Ltd ZYBTMarch 28, 2026 | morningstar.comMZhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGMMarch 25, 2026 | tipranks.comZhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGMFebruary 23, 2026 | tipranks.comZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to ShareholdersFebruary 11, 2026 | markets.businessinsider.comZhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder LetterFebruary 10, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to ShareholdersFebruary 10, 2026 | globenewswire.comWhy Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%January 11, 2026 | aaii.comAIs Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning?September 14, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd trading resumesAugust 22, 2025 | msn.comZhengye Biotechnology Holding Ltd trading halted, volatility trading pauseAugust 21, 2025 | msn.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYBT, ASRT, CNTB, and HURA Company DescriptionsAssertio NASDAQ:ASRT$23.44 -0.01 (-0.04%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$23.44 0.00 (-0.01%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Connect Biopharma NASDAQ:CNTB$2.17 -0.13 (-5.65%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.18 +0.01 (+0.46%) As of 06/5/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.TuHURA Biosciences NASDAQ:HURA$1.97 -0.22 (-10.05%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.96 -0.01 (-0.76%) As of 06/5/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Zhengye Biotechnology NASDAQ:ZYBT$0.83 +0.00 (+0.06%) Closing price 06/5/2026 03:57 PM EasternExtended Trading$0.83 +0.00 (+0.06%) As of 06/5/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
